US EditionPublished • loading... • Updated
Drug-Induced Pneumonitis: The Risk Behind New Cancer Therapies
A Yale review details the rising incidence of drug-induced pneumonitis in lung cancer patients treated with targeted therapies and immunotherapies, urging early symptom awareness.
Summary by Medical Xpress
2 Articles
2 Articles
Medical XpressReposted by 
Yale University
Yale UniversityDrug-induced pneumonitis: The risk behind new cancer therapies
Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, immunotherapies, and emerging antibody–drug conjugates are helping many patients live longer—and live well. But these gains may come with risks, including one called drug-induced pneumonitis, an inflammatory reaction in the lungs that ranges from mild to life-threatening.
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
